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Water soluble vitamins in chronic hemodialysis patients and need for
supplementation. Forty-three patients on chronic hemodialysis who
before the present study had only received a low-dose supplement of
folic and ascorbic acid were studied prospectively for one year. After
baseline values were obtained in month one, increasing doses of
postdialysis vitamin supplements were prescribed for the vitamins
which were found to be insufficient in order to determine the minimal
amount of oral postdialysis supplement necessary to normalize vitamin
levels, According to our results no systematic supplement was indi-
cated for biotin, riboflavin or vitamin B12. For folic acid and vitamin C,
supplementation with lower doses than those prescribed in many
dialysis units allowed optimal vitamin levels in the majority of patients;
2 to 3 mglweek (300 to 400 pg/day) of folic acid and of 1000 to 1500
mg/week (150 to 200 mg/day) of vitamin C was considered sufficient. A
severe pyridoxine deficiency was present in most (> 80%) unsupple-
mented patients, either as judged by pyridoxal-5-phosphate determina-
tions in plasma or determination of specific enzyme activation in
erythrocytes (EGOTo and a-EGOT); a postdialysis supplement of at
least 100 to 150 mg/week of pyridoxine hydrochloride (> 15 to 20
mg/day) corrects this deficiency. The activity of the thiamine-dependent
enzyme transketolase in erythrocytes (ETK0) was insufficient in 35%
and marginal in 21% of the patients, while whole blood thiamine
determined simultaneously in 10 of the ETKo-deficient patients was
within the normal range. These results suggest that in uremia insuffi-
cient transketolase activity may be related to inhibition of the enzy-
matic system rather than to true vitamin deficiency. On a long-term
basis a supplement of 200 to 300 mg/week of thiamine hydrochloride (30
to 45 mg/day) restored ETKo to satisfactory levels in most patients;
whether this supplement is to be recommended warrants further stud-
ies.
The prescription of water-soluble vitamin supplements is
routine practice in many dialysis units. Recently Ailman et al
reported that among ten major dialysis centers in Australia a
supplement of thiamine, riboflavin, pyridoxine, ascorbic acid
and nicotinamide was given in all and of folic acid in eight of the
ten centers [1].
While fat soluble vitamins are known to accumulate in uremia
[2, 31, deficiencies of different water soluble vitamins have been
reported [3—161. However, recent reports questioned the need
for vitamin supplementation, based on the fact that nowadays
hemodialysis (HD) patients are no longer on severely restricted
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diets, that dialysate losses may be lower than previously
considered, and that recent studies in patients receiving sys-
tematic supplementation showed excessively high vitamin lev-
els [17—25]. Literature data are therefore somewhat controver-
sial. A review of literature data reveals two points which may
lead to difficulties regarding a satisfactory comparison of the
reported results. The first is related to the differences in
analytical methods used to assess the vitamin status—either by
microbiological, chemical or enzymatic assays in serum,
plasma or erythrocytes—as these differences could explain
some of the apparently contradictory conclusions reported in
the literature. The second point is that in different studies the
patients differ considerably with respect to whether or not
supplementation had been previously prescribed, which may
unquestionably influence the status of vitamin body stores.
As the patients treated at our center had previously received
only a low-dose supplement of folic acid (< 420 pg/day) and
ascorbic acid (< 85 mg/day), we decided to investigate them
prospectively in order to: (a) study the status of water soluble
vitamins in all the chronic HD patients attending the center and
(b) determine the minimal amount of oral postdialysis supple-
ment giving satisfactory vitamin levels in most of them.
Methods
Patients
All 43 HD patients attending our center at the beginning of
the study were included. Informed consent was obtained from
all. Their mean age was 59 13 years (range 18 to 79) and 25
were male; they had been dialyzed for a mean of 38 months
(range ito 171). The etiologies of CRF were glomerulonephritis
(N = 12), polycystic kidney disease (N = 8), hypertensive (N =
5), diabetic (N = 4) and analgesics nephropathy (N = 3),
chronic pyelonephritis (N = 2), obstructive nephropathy (N =
2) and miscellaneous (N = 7). Twenty-one patients were anuric,
the remainder had a residual diuresis of 200 to 1600 ml/day.
They were on a diet corresponding to a daily protein intake of
0.8 to 1.2 g/kg with individual recommendations concerning
salt, potassium and water intake. Most patients were receiving
a phosphate binder and about a third a supplement of 1-25-
dihydroxy-cholecalciferol (Rocaltrol®). During the study period
erythropoietin therapy was progressively introduced for the
majority of patients. Only a few patients were taking drugs
known to interact with absorption or metabolism of either of the
studied vitamins.
1319
1320 Descombes et a!: Vitamin supplementation and HD
Table 1. Schedule of vitamin prescription
Before
Month
1 2 3 4 5—8 9—12
Biotin — —
Folic acid 1 1 1 1 1 1 1
Vitamin B! — — 100 200 300 100 100
VitaminB2 — —
Vitamin B6 — — 40 80 150 40 40
Vitamin B12 — —
Vitamin C 200 200 200 200 200 200 500
Vitamin doses in mg were given orally after each dialysis session (2 or
3 times a week).
Dialysis therapy
The patients were dialyzed at our center either two (N = 20)
or three (N = 23) times a week with short dialysis sessions; the
mean weekly dialysis time was eight hours and 45 minutes
(range 6 to 12 hours). All patients were dialyzed with a
single-pass monitor using hollow fiber dialyzers, either cellulose
acetate CA 210 (N 17) and CF 23.08 (N = 10) or polyacry-
lonitrile Filtral 12 (N = 3) and Filtral 16 (N = 13). Non-
recirculating dialysate flow was 500 mllmin, the mean blood
flow 345 30 ml/min and the mean ultrafiltration 2.10 0.93
liters per session.
Vitamin prescription
Until the time of this study the patients attending our center
had only been systematically receiving an oral postdialysis
supplement of 1 mg of folic acid (Folvite) and 200 mg of
ascorbic acid (Redoxon®). As the patients were dialyzed two or
three times per week, the weekly doses were therefore 2 to 3 mg
(280 to 420 pg/day) and 400 to 600 mg (55 to 85 mg/day)
respectively. No other vitamin supplements had ever been
given regularly. Questioning all our patients prior to the study
showed that five (12%) had taken irregular supplements of one
or more of the studied vitamins during the months preceding the
study.
During the first month of the study no changes were made in
supplements; all but six of the patients had three determinations
of each studied vitamin and the mean was used as the baseline
value. As preliminary data had shown thiamine and pyridoxine
deficiencies, a postdialysis supplement of these two vitamins
was then given in progressive doses of 100, 200 and 300 mg of
thiamine hydrochloride (Benerva®) and 40, 80 and 150 mg of
pyndoxine hydrochloride (Benadon®; Table 1). The increase
was made on a monthly basis and before each change a new
vitamin determination was obtained at the end of months 2, 3
and 4. Six patients dropped out of the study in this period owing
to transplantation (1), death (1), switching to peritoneal dialysis
(1), refusal to continue the study (1) and transfer to another
center (2).
After the four-month first part of the study, all the patients
received the following doses of oral postdialysis supplement
(Table 1): 1 mg of folic acid, 100 mg of thiamine hydrochloride,
40 mg of pyridoxine hydrochloride and 200 mg of ascorbic acid.
At month 9, as our results had shown insufficient vitamin C
plasma levels in many patients, the postdialysis vitamin C
supplement was increased from 200 to 500 mg. Twelve months
after the initial assessment a new control was performed. For
vitamins Bi, B2, B6 and C, two vitamin determinations were
performed at a week's interval and the mean was considered.
For folic acid and vitamin B 12 a single determination was
performed. Thirty-eight patients were attending our center at
the end of the twelfth month: 27 belonged to the initial cohort
and the remainders had entered our chronic dialysis program in
the previous eight months.
Blood sampling and laboratory determinations
Vitamin Bi status was determined by the transketolase test
(ETK) [26], vitamin B2 status by glutathion-reductase test
(EGR) [27], and vitamin B6 by the glutamate-oxaloacetate
transaminase test (EGOT) [28]. These tests are based on the
estimation of vitamin-dependent red cell enzymes activity be-
fore and after in vitro vitamin supplement. For these determi-
nations vitamin-dependent enzyme activity in erythrocytes was
measured before (ETK0, EGRo and EGOTo) and after addition
of the active form of the respective vitamin. The ratio of
enzyme activity after/before vitamin addition was given as
alpha-ratio (a-ETK, a-EGR and a-EGOT ratios) which is a
measure of the coenzyme-free apoenzyme. If the patient has
adequate stores of the vitamin, then most of the enzyme will
have vitamin bound to it as a cofactor, and the increase in the
activity on the addition of exogenous vitamin will be small, with
an alpha-ratio value near to one. With low vitamin stores,
however, there will be a large increase in the enzyme activity
after exogenous vitamin addition and the alpha-ratio will be
much higher than one. It should be noted that enzyme activity
tests in erythrocytes measure needs for a vitamin in the form of
the coenzyme of specific enzymes at the point of action, so they
reflect the actual intracellular needs. Measuring concentrations
in blood or other tissue stores are more indirect hints correlat-
ing to the real needs only if none of the factors influencing
bioavailability at the point of action are compromised, correct
apoenzyme and coenzyme-binding potency included.
Plasma biotin was determined by the method of Frigg and
Brubacher [29], and plasma vitamin C by the method of
Deutsch and Weeks [30] modified by Brubacher and Vuilleu-
mier [31]. Pyridoxal-5-phosphate was determined in plasma by
the method of Reinken [32]. Whole blood thiamine was deter-
mined according to Vuilleumier et al [33]. Plasma folic acid and
vitamin B12 were determined by radioassay with the [125!]
folate/[57C] vitamin B12 radioassay kit from Baxter Healthcare
Corporation (which uses a purified intrinsic factor as binding
protein for vitamin B 12 determinations). Each determination
was the mean of a duplicated run. Blood for vitamin determi-
nations was always drawn before dialysis. For biotin, folic acid,
vitamin B 12 and vitamin C determinations the blood was placed
into dry heparinized tubes, and for vitamins B!, B2, B6 and
pyridoxal-5-phosphate determinations in ACD tubes. For vita-
min C determinations the plasma was stabilized within an hour
after drawing in a 5% metaphosphoric acid solution. Blood and
plasma samples which were not analyzed rapidly were stored at
—70°.
Statistical analysis
Group comparisons were made with the one way analysis of
variance (ANOVA) and significance was considered for P <
0=
E
0
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Fig. 1. Distribution of plasma biotin
determinations (N = 229). Normal value
> 342 ng/liter.
0.05. Correlation coefficients were determined with the Pear-
son-Product Moment correlation method. The results are re-
ported as mean standard deviation unless otherwise stated. A
systematic analysis was made to statistically compare vitamin
levels with respect to different parameters, namely: age, sex
and weight of the patients, the etiology of renal failure, time on
dialysis and dialysis duration, number of dialyses per week,
type of filter used, the presence or not of residual diuresis and
mean predialysis urea and creatinine values. Sometimes signif-
icant differences were found to be not easily interpretable due
to several possible biases; only the results considered to be
clearly not influenced by such bias are reported.
Results
Biotin
The mean value of all plasma biotin determinations per-
formed during four months was 1340 577 ng/liter (normal
> 342 ng/liter). Figure 1 shows their distribution and that almost
all determinations were either in the normal or high range.
Subnormal values were found four times (1.7%). On the other
hand, more than 70% of the patients had mean values higher
than 1000 ng/liter, the highest values found in the general
population. The patients on HD for more than five years had
significantly higher levels than those having been dialyzed for
shorter periods (1642 873 vs. 1274 740 ng/liter, P < 0.01)
and anuric patients had significantly higher values than those
with residual diuresis (1581 620 vs. 1116 857 ng/liter, P <
0.01).
Vitamin B12
The mean value of the vitamin B 12 plasma concentrations
during the study period was 551 235 pg/liter (normal > 200
pg/liter, N = 282). Almost all individual values were in the
normal range. Low values were observed seven times (2.5%),
but no patient had a long-standing deficiency state, and three
patients had mean values higher than 1000 pglliter. Females had
significantly higher values than males (636 410 vs. 528 280
pg/liter, P < 0.05).
Folic acid
During the study period the mean folic acid (FA) concentra-
tion was 10.41 3.22 ng/liter in patients receiving 1 mg of FA
twice a week and 12.09 3.93 ngfliter in patients treated three
times a week (P < 0.05; normal > 3 nglliter). Figure 2 shows
that most plasma values were in the optimal range between 5
and 15 nglliter. Low values were observed in four samples
(1.5%), but no patient had a long-standing deficiency state.
Similarly, occasional values higher than 20 ng/liter were found,
but no patient had mean values higher than 20 nglliter. These
data suggest that the supplement given was enough to maintain
plasma levels within the optimal range in most patients.
Vitamin C
During the first four months of the study the mean plasma
values were 5.68 2.04 mg/liter in patients receiving 400
mg/week of vitamin C and 7.76 3.87 mg/liter in patients
receiving 600 mg/week (P < 0.05). The patients dialyzed for
more than five years had significantly lower plasma concentra-
tions than those having been dialyzed for shorter periods (5.63
3.25 vs. 7.12 4.08 mg/liter, P < 0.05); 12 patients (27%)
were in the deficient range (< 4 mg/liter) whereas 11 others
(25%) were in the low-normal range (4 to 6.2 mg/liter). In view
of these results the postdialysis vitamin C supplement was
increased from 200 to 500 mg in the second part of the study.
Figure 3 compares the results obtained in month 1 and in month
12 and shows that the higher supplement led to a significant
increase of the mean plasma levels (P < 0.01).
Independently of the dose of vitamin C, elderly patients (> 60
years) had lower plasma concentrations than the younger (P <
0.01). When the 500 mg supplement was introduced patients
dialyzed with polyacrilonytrile filters had significantly lower
plasma levels than those dialyzed with cellulose acetate filters
(6.93 3.61 vs. 11.09 4.90 mg/liter, P < 0.01).
Thiamine (BI)
Figure 4 reports the results of erythrocyte transketolase
determinations according to the different vitamin supplementa-
tion levels. Without supplementation the ETKo value was in
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the insufficient range in 15 patients (35%) and in the marginal
range in nine (21%); the a-ETK was insufficient in two (5%) and
marginal in seven (16%) patients. Thiamine supplementation
rapidly normalized the a-ETK values in almost all patients,
nevertheless, it took longer and higher vitamin doses to nor-
malize ETKo values in the majority of patients. The patients
dialyzed with polyacrilonytrile filters had significantly lower
ETKo levels than those treated with acetate cellulose filters
both without (72.6 9.0 vs. 78.2 12.7 U/liter, P < 0.05) and
with vitamin supplementation (80.7 11.2 vs. 84.4 11.5
U/liter, P < 0.05).
Total whole blood thiamine was simultaneously measured in
10 patients who before supplementation had insufficient (N = 8)
or marginal (N = 2) ETKo values. In these patients the mean
thiamine concentration was normal (84.6 15,7 nmollliter,
normal range 60 to 112 nmollliter) and only one patient, who
was known for concomitant alcohol abuse, had insufficient
levels. After supplementation the whole blood thiamine levels
were higher than normal either with a supplement of 200 to 300
mg/week (145.9 34.3 nmol/liter) or of 600 to 900 mg/week
(156.1 36.5 nmolfliter).
Riboflavin (B2)
The a-EGR index was normal in all patients during the whole
study period. By contrast approximately 10% of the patients
had insufficient and 25% marginal EGRo values. Females had
significantly lower a-EGR and higher EGRo values compared
to males (P < 0.05) and the same was found for older (> 60
years) compared to younger patients (P < 0.01). Patients on
dialysis for more than five years had higher EGRo values (P <
0.05).
Pyridoxine (B6)
Figures 5 and 6 report the results of erythrocyte transaminase
and pyridoxal-5-phosphate (PLP) determinations. These data
1322 Descoinbes et aI: Vitamin supplementation and HD
50
40
30
20
10
00
25
Fig. 2. Distribution of plasma folic acid in
3 6 9 1 2 1 5 1 8 2 1 patients receiving a supple,nent of I mg of
folic acid twice or three times a week (N =
Plasma concentration, ng/ml 269). Normal value > 3 ng/liter.
20
15
10
5
0
5.56±2.87 7.51±4.43 10.19±5.21 10.10±4.45
•
.
•.• .•• .
.
.•
• . •
• •.• . ••.••
• .• 4.
•+. ••
• •. •• .
•••
•:•
• *
•• •• •
.*
..
2x200mg 3x200mg 2x500mg 3x500mg
(57 mg/day) (86 mg/day) (143 mg/day) (214 mg/day)
Fig. 3. Vitamin C plasma levels in patients
receiving 200 mg or 500 mg of ascorbic acid
two or three times a week, Mean values
(± SD) are given at the top of each group. The
area between the solid lines is the normal
range.
1.3
1.25
1.2
x
-
1.15
C
1.1I-Li 1.05
0.95
0.9
140
Descombes et a!: Vitamin supplementation and HD 1323
show a severe vitamin B6 deficiency in the majority of unsup-
plemented patients. EGOTo was in the insufficient range in 33
patients (77%) and in the marginal range in five (12%); the
-EGOT index was insufficient in 28 (65%) and marginal in four
(9%) patients, and PLP respectively in 35 (87%) and two (5%)
patients. Females had significantly higher a-EGOT, lower
EGOTo and lower PLP values than males (P < 0.05). The same
pattern was found for anuric patients dialyzed three times a
week compared to patients with a residual diuresis dialyzed
twice a week (P < 0.01). Patients dialyzed for less than five
years had higher PLP levels than those dialyzed for longer
periods (1.62 1.43 vs. 1,03 0.72 pg/liter, P < 0.05).
When a vitamin supplement was given a-EGOT and PLP
values rapidly normalized in a majority of patients with a
vitamin supplement of 80 to 120 mg/week of pyridoxine hydro-
chloride, but a higher supplement was necessary to normalize
EGOTo (up to 300 to 450 mg/week). With vitamin supplemen-
tation females still had significantly lower PLP levels than males
(8.73 0.4.69 vs. 11.42 4.57 pg/liter, P < 0.01).
Clinical and laboratory data
Table 2 reports the development of some clinical, hemato-
logic and laboratory data from the 27 patients who participated
during the entire study period. There was a progressive increase
of hemoglobin and erythrocyte concentrations due to the intro-
duction of erythropoietin therapy. Significant findings concern-
ing factors influencing vitamin levels have already been re-
ported under each vitamin. It has to be noted that no significant
correlation was found between the vitamin levels and the
patients' weight, the etiology of the renal failure, the number
and duration of the dialysis sessions or the mean predialysis
urea concentrations.
Discussion
The prescription of a supplement of water soluble vitamins to
HD patients is a routine procedure in many centers [1]. This
practice is based on the results of several reports having shown
low levels of various water soluble vitamins in chronic HD
patients, and on the hypothesis that normal vitamin levels and
normal vitamin function are a goal to be achieved [3—16]. The
vitamin supplement is generally given orally, either on a daily
basis or post-dialysis (only once after each dialysis). At our
center it was prescribed on a postdialysis basis as this type of
prescription is associated with good compliance and allows
limiting the number of tablets given to patients who already
have a high number of oral medications.
Rare cases of overt vitamin deficiency, such as scurvy,
beriberi or Wernicke's encephalopathy, have been reported in
HD patients [34—41]. However, vitamin deficiency should be
considered a progressive process that begins long before the
apparition of overt clinical manifestations, which are preceded
by a depletion of body stores and biochemical alterations of cell
metabolism [42, 43]. Not surprisingly therefore, deficiencies of
water soluble vitamins in HD patients have been associated
with several abnormalities such as depression of the immune
response [44, 45], neuropathy [46—49], and impaired amino acid
and lipid metabolism [50, 51], leukocyte hypersegmentation
[52], and bone marrow megaloblastosis [53] or mild scurvy [54].
Nevertheless, there has been recent criticism concerning the
need and/or the doses for supplementation [17—25]. This was
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related to the results of studies showing very high vitamin
concentrations in supplemented patients, levels which would
never be observed in patients with normal renal function [17,
19—25]. It was suggested that the assumption that water soluble
vitamins are non-toxic is based on the fact that in normal
persons the excess is excreted by the kidney [25] and that these
supraphysiological vitamin levels could be associated with side
effects, such as worsening of the uremia-associated secondary
hyperoxalemia by ascorbic acid prescription [19—22].
Deficiency of water soluble vitamins in HD patients has been
mainly attributed to either insufficient intake, excessive losses
in dialysate, or impaired vitamin metabolism [3, 5]. Table 3
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Table 2. Clinical, hematologic and laboratory data in 27 patients during the study year (predialysis values, except for body wt)
Units and normal
values Month 1 Month 5 Month 12
Post-HD body wt kg 61.7 11.9 61.2 12.4 61.9 12.5
Systolic TA mm/Hg 147 15 147 17 147 16
Diastolic TA mm/Hg 82 6.9 83 7.1 82 7.6
Glucose 3.6—6.1 mmol/liter 6.1 1.4 5.7 1.5 5.7 1.1
Urea <7.8 mmol/Iiter 25.4 3.8 26.7 4.5 24.8 3.6
Creatinine <115 tmol/1iter 842 220 892 225 862 182
Uric acid
Total proteins
Cholesterol
180—340 smol/liter
65—80 g/liter
2.5—6,2 mmol/liter
288 71
73.2 5.1
5.37 1.03
285 86
73.2 4.9
4.96 1.06
256 62a,b
68.1 5•2a,b
5.52 l.14'
HDL cholesterol 1.1—2.2 mmol/liter 1.16 0.36 1.15 0.40 1.21 0.37
Triglycerides (N = 11) 1.1—2.3 mmol/liter 1.83 0.56 1.56 0.82 1.84 0.45
Hemoglobin >120 g/liter 92 19 96 17 105 ioa
Hematocrit % 29 4.8 30 6.0 31 3.2a
Erythrocytes 4.5—5.5 T/liter 2.97 0.58 3.10 0.64 3.30 Ø43
MCV 78—96 93.1 4.4 92.6 5.8 92.7 5.2
Thrombocytes 150—300 G/Iiter 216 53 206 66 232 64
Leukocytes 4.0—10.0 G/liter 5870 2060 5298 1640 6167 1892
% Segmented % 61.6 10.8 62.9 10.9 59.1 9.9"
Total lymphocytes 1.0—4.0 G/liter 1139 462 1163 574 1434 672'
a P < 0.05 compared to initial values
b P < 0.05 compared to month 5
Table 3. Recommended dietary allowance for normal persons and
calculated vitamin content of diets with different protein intakea
Vitamin Units
Recommended
dietary
allowance
Daily protein i
giday
ntake
40 60 80
Biotin g 100—200 13.40 17.80 15.80
Folic acid g 400 260 290 320
Vitamin B! mg 1.2—1.6 0.60 1.00 1.10
Vitamin B2 mg 1.2—1.8 0.80 1.20 1.80
Vitamin B6 mg 1.6—2.2 1.00 1.20 1.50
Vitamin B12
.ag 3 2.30 3.20 5.10
Vitamin C mg 40—60 86 87 88
a Adapted from references [3, 5].
reports the vitamin content of different diets compared to the
recommended dietary allowance. This table shows that for diets
containing less than 40 grams of protein/day the vitamin intake
can be quite below the recommended amounts, but that this
difference is much less for diets containing 60 to 80 grams of
protein/day. Limited data are available concerning vitamin
losses during HD. Concerning vitamin C, Sullivan and Eisen-
stein reported that 80 to 280 mg are lost per procedure, which
exceeds either daily intake and normal losses in urine [54, 55].
Gang et al recovered only 70 to 135 g of pyridoxal-5-phosphate
in dialysate per procedure (7 hr HD), which corresponds to the
urinary daily losses in normal persons [56]. Estimated folic acid
losses range from 10 to 250 g per procedure [52, 57—59],
whereas Kesse-Elias et al were unable to detect vitamin B12 in
dialysate [601.
According to these data, it appears that the intake of some
vitamins may not be so low and losses in dialysate not so
important as was previously considered. However, vitamin
intake and dialysate losses per se do not give comprehensive
information concerning the vitamin status at a given time,
which also depends on the status of body stores. The amount of
Table 4. Vitamin stores in humansa
Vitamin B12 3—5 years
Folic acid 1—1.5 years
Vitamin B2 3—4 months
Vitamin B6 3—4 months
Vitamin C 3—4 months
Vitamin BI 4—10 days
a Adapted from Schaeffer et al [61.
body stores varies greatly according to the vitamin, as shown in
Table 4, and of course directly depends on the vitamin intake
during the previous weeks or months. This point is important in
the evaluation of some recent longitudinal studies performed in
patients previously supplemented and in which the vitamin
supplement was withdrawn—a situation quite different to the
one of patients who have never received any vitamin supple-
ment and who may present long-standing depleted stores. For
example, in two studies in which vitamin C supplement was
withdrawn the plasma levels fell from supraphysiological to
normal or lower-normal values in a period of 12 to 24 months
[61, 62], a finding in sharp contrast with the data of several
papers concerning patients who had never been supplemented
showing a severe vitamin C deficiency in most patients [7—10,
54, 55, 63—67]. Similar discrepancies also exist for folic acid
when comparing the results from studies performed on never
supplemented patients [4, 15, 16, 53, 57] to those in which the
vitamin supplement was withdrawn [17, 58, 61, 68, 691. There-
fore, we consider that the question concerning the need for
vitamin supplementation can more satisfactorily be answered
by studies performed in patients who never received any extra
supplement.
Another point that may contribute to vitamin deficiency is
impaired metabolism [3, 5]. Some reports have shown evidence
of abnormal metabolism of certain water soluble vitamins,
particularly pyridoxine and thiamine. Ross et al showed in
1326 Descombes et al: Vitamin supplementation and HD
CAPD patients that while total pyridoxine (including non-active
metabolites of the vitamin) determined by microbiological
methods was normal in all patients, pyridoxal-phosphate (PLP),
the principal active form of the vitamin, was severely deficient
in 63% [701. This discrepancy suggested that in spite of normal
vitamin levels the vitamin metabolism is impaired in uremia [70,
71]. Concerning thiamine, Sterzel et al showed in vitro that the
thiamine-dependent enzyme transketolase is inhibited by dia-
lyzable low-molecular-weight substance(s) [72]. The results
obtained for thiamine in the present study in the patients with
low ETKo activity in which whole body thiamine was simulta-
neously determined (and was normal) also suggest that an
impaired metabolism (of the apoenzyme) rather than true vita-
min (coenzyme) deficiency accounts for the abnormal transke-
tolase activity.
According to previous discussion, it appears that the com-
parison of the results reported in the literature may be influ-
enced by several factors, and has to be made cautiously
considering, if possible, all the different elements influencing
the vitamin status as well as its assessment. Furthermore, our
data analysis shows that among the points discussed above, the
status of each individual vitamin may depend on several ele-
ments as different as sex (riboflavin, pyridoxine, vitamin B12),
age (riboflavin, vitamin C), residual diuresis (biotin, pyridox-
me), time on dialysis (biotin, riboflavin, pyridoxine, vitamin C),
or the type of filter used (thiamine, vitamin C), which makes
data comparison even more complex.
Our results concerning biotin, riboflavin and vitamin B12
which show normal to high values in most of unsupplemented
patients are in agreement with most reports in literature. For
biotin previous investigators reported normal or high values [4,
63, 73]. Our data also show normal to supranormal levels, and
the progressive increase of biotin levels with time on dialysis
and the higher levels in anuric patients suggest that the epura-
tion of this vitamin by the artificial kidney is less than that by
the natural one. Normal to high total riboflavin levels were
reported in plasma and blood cells [63, 74, 75]. Low EGRo
activity was found in only 10% of our patients, a similar figure
to that reported by Myldeck et al; this author reported that EGR
values normalized with a daily supplement of 2 mg/day [76]. For
vitamin Bl2 all investigators except two [47, 77] reported
normal or high plasma levels compared to controls [4, 15, 16,
53, 61, 63, 69, 74, 78].
Folic and ascorbic acids have been classically supplemented
in HD patients at doses up to 1 to 5 mg/day and 200 to 1000
mg/day, respectively [3, 5, 22, 79, 80]. These supplement doses
were found to be associated with very high vitamin levels in
several studies [17—24]. Our data agree with recent reports
suggesting that lower doses than those previously prescribed
are sufficient. In our study a postdialysis supplement of 2 to 3
mg/week (300 to 400 pjg/day) of folic acid and of 1000 to 1500
mg/week (150 to 200 mg/day) of vitamin C allowed normal
vitamin levels in the great majority of patients. Folic acid doses
we propose approximate the daily dietary allowance, whereas
for vitamin C the proposed doses are about three times higher.
Recent works have pointed out that excessive vitamin C
supplementation can worsen uremia-related secondary hyper-
oxalemia [19—22]. In this respect it is worth noting that with the
supplementation given few patients had supranormal plasma
values, within levels that according to the study of Pru et al,
should not be associated with significant hyperoxalemia [20].
Although oxalic acid was not measured in our patients, we
believe that the supplementation we propose should be safe in
this respect. However, it should be noted that the question of
whether different modalities of vitamin prescription (daily or
postdialysis prescription) may have different effect on oxalic
acid metabolism has not be addressed by the present study, and
is still unanswered.
Because of impaired metabolism the appreciation of pyridox-
me status in HD patients will depend on the method used to
assess the vitamin status. While authors who measured total
pyridoxine [61, 63, 69, 74] report normal to high concentrations,
all authors who measured either pyridoxal-5-phosphate (PLP),
the main active form of the vitamin, [11, 13, 48, 56] or
transaminase erythrocyte activity [11, 12, 44, 45, 50, 81] con-
cluded that unsupplemented HD patients present severe pyri-
doxine deficiency. Both PLP and transaminase determinations
were performed concurrently in our study and show a severe
deficiency of the active form of this vitamin. This deficiency can
be corrected by pharmacological doses of 100 to 150 mg/week
(>15 to 20 mg/day) of pyridoxine hydrochloride, a dose higher
than the 10 mg/day proposed by Kopple et al [12]. The reason
for this difference is not clear, but may be related to the
different mode of prescription of the vitamin supplement (daily
vs. postdialysis prescription).
For thiamine, as for pyridoxine, the appreciation of the status
depends on which parameter is studied. All authors except one
[74] who determined total thiamine reported normal or even
high levels in plasma, blood or leukocytes [61, 63, 82, 83]. By
contrast, authors who studied transketolase activity report
normal [84, 85] to low levels [72, 86, 87]. Our results show that
despite normal a-ETK values in most patients and normal
thiamine levels (in the 10 patients in whom this parameter was
also measured), ETKo levels were low or marginal in 56% of
our patients. Sterzel et al and Lonergan et al reported that the
inhibition of transketolase activity could be reversed by dialysis
but not by vitamin supplementation [72, 86]. Contrary to their
conclusions our results show that transketolase activity may be
normalized by pharmacological doses of thiamine hydrochlo-
ride (> 200 to 300 mg/week, 35 to 40 mg/day); whether this
supplement is to be recommended cannot be stated from our
data alone.
In conclusion, our results and the above discussion suggest
that the vitamin status in an individual dialyzed patient depends
on several different interacting factors including sex, age, actual
vitamin intake, previous supplementation, dialysate losses,
residual kidney function, time on dialysis and the type of filter
used. Impaired metabolism also plays an important role, and
further studies in this field are needed to understand better
vitamin nutrition and metabolism in the uremic population.
Ideally vitamin prescription should be based on individual
monitoring. However, due to the number of patients on dialy-
sis, this procedure is both time consuming and too expensive;
therefore, from a practical point of view a population-based
approach should be considered. Ace rding to our results no
systematic supplement seems to be ii dicated for biotin, ribo-
flavin and vitamin B12. Supplementation of folic acid and
vitamin C with lower doses than those previously prescribed in
many dialysis units allows optimal vitamin levels in the majority
of patients. A postdialysis supplement of 2 to 3 mg/week (300 to
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400 pg/day) of folic acid and of 1000to 1500 mg/week (150 to 200
mg/day) of vitamin C can be considered sufficient and safe. To
correct pyridoxine deficiency a postdialysis supplement of at
least 100 to 150 mg/week of pyridoxine hydrochloride (> 15 to
20 mg/day) should be considered. The prescription of 200 to 300
mg/week of thiamine hydrochloride (30 to 45 mg/day) normal-
izes erythrocyte transketolase activity in most HD patients in
which this parameter is insufficient. Whether this supplement is
to be recommended warrants further studies.
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